AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03442621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant with a moderate breakfast
Description: Relacorilant, presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10 h fast and 0.5 h after the start of a moderate breakfast
Study NCT03240679 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acell MatriStem® Surgical Matrix
Description: Extracellular matrix (ECM) product that is composed of collagen and natural proteins that provide a re-absorbable scaffold for tissue remodeling to facilitate constructive healing following endoscopic submucosal resection (EMR). Covers the defect site following mucosal resection using endoscopy clips or X-tac. The device will remain attached to the esophagus and integrate with native tissue over time.
Study NCT02109120 — intervention group
Intervention type: PROCEDURE
Intervention: vein blood collection
Description: 5 ml peripheral vein blood samples were collected from each patient admitted to our study at the following time-points：Pre-operative（morning of surgery），just before declamping，30mins after declamping and post-operative（12h）.
Study NCT01996826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin® (bevacizumab)
Description: One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
Study NCT01996826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl & Refresh Liquigel
Description: One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks.
Study NCT01758185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant hepatitis b vaccine
Description: 0.5ml intramuscular
Study NCT01758185 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: recombinant hepatitis b vaccine
Description: 0.5ml intramuscular
Study NCT01758185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aleph influenza vaccine
Description: 0.5ml intramuscular
Study NCT01758185 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Aleph influenza vaccine
Description: 0.5ml intramuscular
Study NCT04564456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent
Description: 2 inhalations of Test oproduct in one study period
Study NCT04564456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADVAIR DISKUS® 500/50
Description: 2 inhalations Reference product in one study period
Study NCT01086540 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants receive rituximab intravenous (IV) infusions, 1000 mg each, 14 days apart (Day 0 and Week 2).~Rituximab is supplied as a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials, which must be diluted before administration~Standard rituximab pre-medications will be provided in preparation for the rituximab infusions.
Study NCT01086540 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive placebo intravenous (IV) infusions 14 days apart (Day 0 and Week 2).~Standard pre-medications will be provided in preparation for the infusions.
Study NCT01086540 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: CMRI
Description: Up to 20 participants from each treatment arm will be assessed by CMRI at Baseline and at Week 24.
Study NCT01086540 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CMRI
Description: Up to 20 participants from each treatment arm will be assessed by CMRI at Baseline and at Week 24.
Study NCT01086540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prednisone
Description: Prednisone dose of 40 mg (or equivalent) by mouth administered the night before and the morning of each study drug infusion.
Study NCT01086540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Prednisone dose of 40 mg (or equivalent) by mouth administered the night before and the morning of each study drug infusion.
Study NCT00774592 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and Family Life Curriculum (HFLE)
Description: Standard Grade 10 curriculum
Study NCT00774592 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health and Family Life Curriculum (HFLE)
Description: Standard Grade 10 curriculum
Study NCT03006718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS for Pain Management App
Description: At hospital discharge, the investigators will collect baseline surveys, a blood sample, and download the PROMIS for Pain Management App onto the subject's mobile device. For five consecutive weeks, PROMIS measures will be collected through weekly surveys. The investigators plan to compensate patients for their time. Patients will come back to the hospital after 35 days for a final blood draw and set of surveys. In the event a patient gets readmitted, the investigators will record that admission. The investigators will also collect Proxy PROMIS measures from parents of participants between the ages of 8 and 17-years who have agreed to participate in the study. It is the goal of the investigators to engage one of the parents in the reporting of weekly validated Proxy PROMIS measures.
Study NCT01655082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0116 transdermal patch
Description: One patch per day (during 24 hours) for 21 days
Study NCT01655082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine transdermal patch
Description: One patch per day (during 24 hours) for 21 days
Study NCT00078832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: aromatase inhibitor
Study NCT00078832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Arimidex placebo
Study NCT01030263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluorescence-aided confocal endomicroscopy guided biopsy.
Description: Fluorescence-aided confocal endomicroscopy guided biopsy.
Study NCT01030263 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Random four-quadrant biopsies.
Description: Random four-quadrant biopsies.
Study NCT01455948 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Relieva Balloon Sinuplasty™ System
Description: Catheter-based devices used to dilate blocked paranasal sinus ostia (openings).
Study NCT01455948 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Endoscopic Sinus Surgery
Description: Specialized probes are used to cannulate closed ostia (openings), and small forceps are used to resect periostial bone and tissue to enlarge the sinus ostia.
Study NCT03191448 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge preservation
Description: Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously.
Study NCT03191448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDBA
Description: Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously. In this study a freezed dried bone allograft (FDBA) will be used and the site will be covered with a collagen wound dressing (Collaplug)
Study NCT03191448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collagen wound dressing
Description: Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously. In this study a freezed dried bone allograft (FDBA) will be used and the site will be covered with a collagen wound dressing (Collaplug)
Study NCT03608111 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: single task balance training
Description: single task balance training
Study NCT03608111 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dual task balance training
Description: dual task balance training
Study NCT02689011 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block
Description: For patients in Femoral nerve Block Group (Group F), ultrasound guided Femoral nerve block was performed using 0.375% bupivacaine, 20 ml for femoral nerve
Study NCT02689011 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Description: Patients in Epidural Group (Group E) were turned in lateral position for epidural catheter placement in lumbar region. Epidural was loaded with 0.25% bupivacaine and infusion of M2 (Bupivacaine 0.1% + Fentanyl 2mcg/ml) was started at 8 - 12 ml per hour.
Study NCT02237482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trilogy cup
Study NCT02237482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trabecular metal cup (TM)
Study NCT02237482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZCA cup
Study NCT00861991 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Perspective taking instruction
Description: Students were asked to take the perspective of their standardized patients during clinical skills examinations
Study NCT01589913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICD-Forum
Description: The CBT based internet program ICD-Forum is designed to increase QoL, and decrease anxiety and depression in ICD-patients. The program includes a therapist moderated asynchronous discussion group and content focused modules following a six weeks schedule:~1. Introduction to participants and online system~2. Knowledge regarding ICDs~3. Strategies for behavior change~4. Psychological models for anxiety and depression~5. Strategies to cope with avoidance, anxiety and depression~6. Resume, evaluation, resolution of open questions, goal setting, good bye
Study NCT01086540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone
Description: Methylprednisolone (or equivalent corticosteroid) administered intravenously 30 minutes prior to each study drug infusion.
Study NCT01086540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Methylprednisolone (or equivalent corticosteroid) administered intravenously 30 minutes prior to each study drug infusion.
Study NCT02090790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iv dexamethasone
Description: 2 ml 8 mg iv dexamethasone
Study NCT02090790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: femoral dexamethasone
Description: 2ml 8mg dexamethasone administration added 30 ml 0,5 % bupivacain
Study NCT02090790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: serum physiologic
Description: 2 ml iv serum physiologic
Study NCT00084656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: IV over 90 mins on day 1, wks 1,9,17,25,33,41,53 Dose: 3 mg/kg (Part I), 10 mg/kg (Part II)
Study NCT00084656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tyrosinase/gp100/MART-1 Peptides
Description: (All subjects in Part I and HLA-A\*0201 positive subjects only in Part II): SC, day 1 of wks 1,3,5,7,9,11,17, 21,25,33,41,53 Dose: 1 mg peptide emulsified in 1 mL Montanide ISA 51 VG.)
Study NCT02438813 — intervention group
Intervention type: DRUG
Intervention: Deoxycholic acid
Description: Deoxycholic acid (ATX-101) injection as the treatment of SMF as per standard of care in clinical practice.
Study NCT02438813 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical Procedures
Description: Surgical procedures for treatment of SMF as per standard of care in clinical practice.
Study NCT02438813 — intervention group
Intervention type: PROCEDURE
Intervention: Laser Liposuction
Description: Laser Liposuction for the treatment of SMF as per standard of care in clinical practice..
Study NCT02438813 — intervention group
Intervention type: DEVICE
Intervention: Energy Devices
Description: Energy Devices for the treatment of SMF as per standard of care in clinical practice.
Study NCT02438813 — intervention group
Intervention type: OTHER
Intervention: Other Treatments
Description: Other treatments for SMF as per standard of care in clinical practice.
Study NCT03968185 — intervention group
Intervention type: OTHER
Intervention: Interfascial infiltration
Description: Injection of L-bupivacaine (50 mg) and dexamethasone (4 mg) in the interfascial space under ultrasound guidance.~Patients were kept under surveillance for at least one hour before discharge.~Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief.
Study NCT03968185 — intervention group
Intervention type: OTHER
Intervention: Standard medical treatment
Description: Standard medical treatment include acetaminophen, NSAIDs and muscle relaxant as first line pharmacological treatment and escalation to analgesics level II or morphine if required, as needed for low back pain, in agreement with national guidelines Route of administration (orally or iv) was let at the discretion of the attending emergency physician.~Patients were kept under surveillance for one hour before discharge. Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief.
Study NCT03113604 — intervention group
Intervention type: OTHER
Intervention: Study on samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma
Description: Retrospective study of samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma (HCC): three groups of samples will be selected:~Group 1: Tumor and peri-tumor tissue samples from patients with non-treated sorafenib CHC (surgical resection or other) Group 2: Tumor and peri-tumor tissue samples from tumor and peritumor tissues of patients not responding to sorafenib treatment Group 3: samples from patients responding to treatment with sorafenib
Study NCT01629472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VSLA + Gender dialogue groups
Description: Dialogue groups discussing household discussion making and gender norms facilitated by IRC.
Study NCT01629472 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VSLA + Gender dialogue groups
Description: Dialogue groups discussing household discussion making and gender norms facilitated by IRC.
Study NCT02074813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training
Study NCT03394690 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: green coffee
Description: 2 capsuls
Study NCT03394690 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: 2 capsuls
Study NCT01260545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA-18C3
Description: 2.5 mg/kg, 3.75 mg/kg IV (in the vein) on Day 1 of each 14 day cycle until the subject is no longer benefiting clinically or unacceptable toxicity occurs.
Study NCT00409344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: A continuous infusion of dexmedetomidine will be started at a dose of 0.8mcg/kg/hr. This will continue for no longer than 24 hours. Four hours post extubation the study drug wii be discontinued using a standard tapering protocol: 0.6mcg/kg/hr for 4 hours then 0.4mcg/kg/hr for 4 hours, then 0.2 mcg/kg/hr for 4 hours and then 0.1mcg/kg/hr for 4 hours and then turned off.
Study NCT00409344 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline will be given as the placebo and will administered at 0.8mcg/kg/hr
Study NCT00409344 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline will be given as the placebo and will administered at 0.8mcg/kg/hr
Study NCT04598269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-1777
Description: ATI-1777 topical solution 2.0% w/w
Study NCT04598269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle topical solution containing no ATI-1777
Study NCT03550404 — intervention group
Intervention type: BEHAVIORAL
Intervention: Seasons of Care App
Description: A web-based mobile application (app) called the Seasons of Care Elder Navigation Guide will assist elders, their families/caregivers, healthcare providers, outreach workers, and other community members in navigating healthcare and insurance systems. The app has the added advantage of being easy to update to respond to future changes in health care and insurance, and sustainable because it is not dependent on intensive training, developing, and retaining of individuals in professional navigation positions.
Study NCT01027260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itopride HCI 50 mg
Description: Variable dosing
Study NCT01027260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itopride HCI 100 mg
Description: Variable dosing
Study NCT01027260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Variable dosing
Study NCT01175395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI-20089/Lucentis
Description: Combining a single dose of IBI-20089 (6.9 mg or 13.8 mg) intravitreal injection adjunctively with Lucentis 0.5 mg intravitreal injection at baseline and monthly intravitreal Lucentis injection PRN based on clinical and OCT results.
Study NCT04400929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Dosage for IV Leukine® injection: 125mcg/m2/day over a 4-hour period for up to 5 days.
Study NCT04400929 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 0.9%
Description: IV normal saline 0.9% for 5 days
Study NCT03869333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Invaplex[AR-DETOX]
Description: Detoxified Shigella flexneri 2a Artificial Invasin Complex (Invaplex\[AR-Detox\]) Vaccine
Study NCT03869333 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT01672866 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match SIM via subcutaneous injection every week
Study NCT01672866 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SIM
Description: Subcutaneous injection every week
Study NCT01672866 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIM
Description: Subcutaneous injection every week
Study NCT03155308 — intervention group
Intervention type: DEVICE
Intervention: Pentax chromoendoscopy (i-scan and Optical Enhancement)
Description: All lesions will be evaluated using the 3 i-scan modes and the 2 OE modes without magnification. The lesion size data, location and macroscopic shape of the lesions based on the Paris classification will be recorded. Finally all lesions will be classified in real-time into 3 types based on NICE classification (NICE 1, hyperplastic polyps; NICE 2, adenoma and superficial submucosal carcinoma; NICE 3, SM-d invasive carcinoma). A level of confidence (high or low) will be assign in each stage. Polyp's images will be photographically and videotape recorded. All polyps will be resected or biopsied for histopathological examination used as the criterion standard for the analysis.
Study NCT00438152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saquinavir (Invirase®)
Description: Saquinavir 1000mg + Ritonavir 100mg Bd for 24 weeks
Study NCT00438152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir (Kaletra®)
Description: Lopinavir/ritonavir 400/100 mg BD 24 weeks
Study NCT02190890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Study NCT02190890 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study NCT01389323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablet, Oral, 60 mg, once daily, 24 weeks
Study NCT01389323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-Interferon Alfa-2a
Description: Syringe, Subcutaneous Injection, 180 μg, Once weekly, 24 or 48 weeks depending on response
Study NCT01389323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 or 48 weeks depending on response
Study NCT01915823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelastine hydrochloride and fluticasone propionate
Study NCT01915823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dymista vehicle
Study NCT04133714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multi-channel tDCS
Description: multi-channel transcranial direct current stimulation, tDCS
Study NCT04133714 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: multi-channel tDCS
Description: multi-channel transcranial direct current stimulation, tDCS